NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Company Overview - NeuroNOS is a biopharmaceutical company focused on developing treatments for Autism Spectrum Disorder (ASD) and other neurological conditions, including Alzheimer's disease and brain cancers [2][9] - The company has secured an initial $2 million in equity financing to accelerate the preclinical development of its small-molecule drug designed for children with autism [2][3] Drug Development - The drug under development aims to regulate nitric oxide (NO) levels in the brain, which has shown promise in improving neurological function [2][3][9] - NeuroNOS is currently in advanced stages of formulation development, focusing on a subcutaneous injection with plans for an oral formulation to enhance accessibility for pediatric patients [6][9] Research and Scientific Basis - The research supporting NeuroNOS's drug is based on findings from Prof. Haitham Amal, indicating that children with ASD exhibit elevated NO levels, and inhibiting NO production can reverse autism-like phenotypes in models [3][4] - The partnership with the Hebrew University has validated these findings in over 700 animals and human stem cell-derived neurons, providing biological evidence of NO dysregulation's role in ASD [4][8] Market Context - Autism Spectrum Disorder is a complex neurodevelopmental condition affecting millions globally, with rising prevalence rates intensifying the need for effective treatments [7][8] - Currently, there are no FDA-approved drugs targeting the biological mechanisms underlying ASD, highlighting a critical gap that NeuroNOS aims to address [8]